Health
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19 – GlobeNewswire
Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
CALGARY, Alberta, March 03, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) and QIMR Berghofer Medical Research Institute (QIMR Berghofer), one of Australias most successful medical research institutes, announced today the publishing of a new article providing evidence of apabetalones potential benefit on SARS-CoV-2 (COVID-19). The article, titled: Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical),…
-
Noosa News8 hours agoHow Lily Steele-Park took her rapist to court and won
-
General22 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business13 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General24 hours agoFears for next anti-Semitic firebombing on home soil